MedTrace Logo

Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)

NCT01669668 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-07-16

No results posted yet for this study

Summary

This phase II trial studies how effectively radiofrequency ablation prevents recurrence of hepatocellular carcinoma (HCC) in patients with easily removable tumors. Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells.

Conditions

  • Carcinoma, Hepatocellular

Interventions

PROCEDURE

radiofrequency ablation

Undergo RFA

PROCEDURE

laparoscopy

Undergo laparoscopic ultrasound

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Steven Strasberg, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01669668 on ClinicalTrials.gov